Search - tctmd.com

Displaying 81 - 100 of 118

Sort: Relevancy | Date

Presentation TCT 2016

How Would I Treat? (Option 2)

Presenter: Runlin Gao, Bo Xu, Zening Jin

November 01, 2016

Presentation TCT 2016

How Would I Treat? (Option 1)

Presenter: Runlin Gao, Bo Xu, Philippe Généreux

November 01, 2016

Presentation TCT 2016

Case Introduction: How Should I Treat?

Presenter: Runlin Gao, Bo Xu, Kefei Dou

November 01, 2016

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Presentation TCT 2016

Case #3: A Novel Issue With a Bioresorbable Scaffold

Presenter: Antonio Colombo, Jeffrey W. Moses, Carlo Di Mario

October 31, 2016

Presentation TCT 2016

Case 3:

Presenter: Parag Barwad, Raju Narasa Kavalipati, Narenda N. Khanna, Fazila T. Malik, Manotosh Panja, Gokul M. Reddy, Kamal K. Sethi, Rabin dra Nath Chakraborty

October 31, 2016

Presentation TCT 2016

Case 3: Heavily Calcified Vessel

Presenter: Jun-Jack Cheng, Gary S. Mintz, Chiung Jen Wu, Wen-Lieng Lee

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Philip Green

October 31, 2016

Title Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presentation TCT 2016

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Suzanne Baron

October 31, 2016

Presentation TCT 2016

Case #3: CTO PCI: Keep It Simple

Presenter: Afzalur Rahman, Kaisar Nasrullah Khan

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TCT 2015

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves

Presenter: John D. Carroll, Ioanna Kosmidou, Danny Dvir

October 15, 2015

Presentation TCT 2015

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

Presenter: Ariel Finkelstein, Ganesh Manoharan, Susheel Kodali

October 14, 2015

Presentation TCT 2015

TCT 95: The Long-term Hemodynamic Performance of Transcatheter Aortic Valve Replacement A Report From the PARTNER I Trial

Presenter: Jeffrey J. Popma, Mathew Williams, Melissa Daubert

October 13, 2015

Presentation TCT 2015

TCT 93: Improvement in Renal Function and Its Impact on All-Cause Mortality After Transcatheter Aortic Valve Replacement (TAVR) Experience From the PARTNER Trial

Presenter: Jeffrey J. Popma, Mathew Williams, Nirat Beohar

October 13, 2015

Advertisement

How Would I Treat? (Option 2)

How Would I Treat? (Option 1)

Case Introduction: How Should I Treat?

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Case #3: A Novel Issue With a Bioresorbable Scaffold

Case 3:

Case 3: Heavily Calcified Vessel

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Case #3: CTO PCI: Keep It Simple

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Study Design for the PARTNER 3 Low-Risk Trial

PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves

FDA-Approved or US IDE Studies: SAPIEN 3 - Technical Specifications and Clinical Trial Results (CE Studies and PARTNER II S3HR and S3i)

TCT 95: The Long-term Hemodynamic Performance of Transcatheter Aortic Valve Replacement A Report From the PARTNER I Trial

TCT 93: Improvement in Renal Function and Its Impact on All-Cause Mortality After Transcatheter Aortic Valve Replacement (TAVR) Experience From the PARTNER Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content